Prof. Dr. BAŞAK OYAN ULUÇ

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners , cilt.22, ss.157-60, 2016 (SCI-Expanded)

30. May there be a role for hormonal manipulation for treatment of hormone receptor negative breast cancer?

Onder E., Uysal S., Oyan B.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology , cilt.20, ss.1380, 2015 (SCI-Expanded) Sürdürülebilir Kalkınma

31. Cutaneous melanoma in Turkey: analysis of 1157 patients in the Melanoma Turkish Study

Abali H., ÇELİK İ., Karaca B., TURNA Z. H., KAYTAN SAĞLAM E., Akman T., et al.

JOURNAL OF BUON , cilt.20, sa.4, ss.1137-1141, 2015 (SCI-Expanded)

32. Development of acute pulmonary hypertension after bortezomib treatment in a patient with multiple myeloma: a case report and the review of the literature.

Akosman C., Ordu C., Eroglu E., Oyan B.

American journal of therapeutics , cilt.22, sa.3, 2015 (SCI-Expanded)

33. Revisiting post-gastrectomy anemia with a brief survey among a group of Turkish medical oncologists.

Eren O., Sonmez Ö., Ozkan H., Oyan B.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology , cilt.20, ss.808-11, 2015 (SCI-Expanded)

34. Comparison of metabolic and anatomic response to chemotherapy based on PERCIST and RECIST in patients with advanced stage non-small cell lung cancer.

Ordu C., Selcuk N., Akosman C., Eren O., Altunok E., Toklu T., et al.

Asian Pacific journal of cancer prevention : APJCP , cilt.16, ss.321-6, 2015 (SCI-Expanded) Sürdürülebilir Kalkınma

35. Voltage-gated sodium channel blockers can augment the efficacy of chemotherapeutics by their inhibitory effect on epithelial-mesenchymal transition.

Eren O., Ozturk M., Sonmez Ö., Oyan B.

Medical hypotheses , cilt.84, ss.11-3, 2015 (SCI-Expanded)

36. Voltage-gated sodium channel blockade for inhibition of EMT.

Eren O., Oyan B.

Trends in pharmacological sciences , cilt.35, ss.621, 2014 (SCI-Expanded)

37. Should we be more cautious about replacement of vitamin B12 in patients with cancer receiving cytotoxic chemotherapy?

Eren O., Ozturk M., Sonmez Ö., Oyan B.

Medical hypotheses , cilt.83, ss.726-9, 2014 (SCI-Expanded) Sürdürülebilir Kalkınma

38. Pituitary metastasis of colon adenocarcinoma: a rare occurrence.

Ozturk M., Eren O., Sarikaya B., Aslan E., Oyan B.

Journal of gastrointestinal cancer , ss.85-7, 2014 (SCI-Expanded)

39. Gastric metastasis in a patient with lobular breast carcinoma 6 years after diagnosis.

Eren O., Ozturk M., Sonmez Ö., Aslan E., Ozkan F., Oyan B.

Journal of gastrointestinal cancer , cilt.45, ss.504-5, 2014 (SCI-Expanded)

40. Bone health in breast cancer patients: A comprehensive statement by CECOG/SAKK Intergroup

Rordorf T., Hassan A. A., Azim H., Alexandru E., ER O., Gokmen E., et al.

BREAST , cilt.23, sa.5, ss.511-525, 2014 (SCI-Expanded)

41. Cancer-related fatigue: can it be due to adrenal suppression secondary to high-dose steroids used as antiemetic?

Eren O., Ozturk M., Oyan B.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer , cilt.22, ss.2599-600, 2014 (SCI-Expanded) Sürdürülebilir Kalkınma

42. Does cetuximab cause small bowel perforation?

Ozturk M., Eren O., Oyan B.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology , cilt.19, ss.865, 2014 (SCI-Expanded)

43. Reply to the letter to the editor 'Are male gender and nonadenocarcinoma histology valid prognostic factors for breast cancer?' by Eren et al.

Eren O., Ozturk M., Sonmez Ö., Oyan B.

ANNALS OF ONCOLOGY , cilt.25, sa.4, ss.911, 2014 (SCI-Expanded) Sürdürülebilir Kalkınma

44. Gallbladder perforation related to bevacizumab.

Ozturk M., Kalayci M., Oyan B.

Clinics and research in hepatology and gastroenterology , cilt.37, 2013 (SCI-Expanded)

45. HER2-targeted therapy in breast cancer: a systematic review of neoadjuvant trials.

Dent S., Oyan B., Honig A., Mano M., Howell S.

Cancer treatment reviews , cilt.39, ss.622-31, 2013 (SCI-Expanded) Sürdürülebilir Kalkınma

46. Takotsubo syndrome: an underdiagnosed complication of 5-fluorouracil mimicking acute myocardial infarction.

Ozturk M., Ozveren O., Cinar V., Erdik B., Oyan B.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis , cilt.24, ss.90-4, 2013 (SCI-Expanded)

47. Why do targeted agents not work in the adjuvant setting in colon cancer?

Oyan B.

Expert review of anticancer therapy , cilt.12, ss.1337-45, 2012 (SCI-Expanded) Sürdürülebilir Kalkınma

48. Potential role of bone-directed therapy on the superiority of aromatase inhibitors over tamoxifen.

Oyan B.

Medical hypotheses , cilt.77, ss.1028-30, 2011 (SCI-Expanded)

49. The early metabolic effect of zolendronic acid on FDG-PET scans in patients with bone metastasis

Selcuk N. A., Uluc B., Akosman C., Ordu C., Toklu T.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING , cilt.38, 2011 (SCI-Expanded)

50. The prognostic relevance of response evaluation to chemotherapy by FDG-PET/CT in patients with metastatic non-small-cell lung cancer

Selcuk N. A., Uluc B., Ordu C., Akosman C.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING , cilt.38, 2011 (SCI-Expanded)

51. Unicentric mixed variant Castleman disease associated with Hashimoto disease: the role of PET/CT in staging and evaluating response to the treatment.

Akosman C., Selcuk N. A., Ordu C., Ercan S., Ekici I. D., Oyan B.

Cancer imaging : the official publication of the International Cancer Imaging Society , cilt.11, sa.1, ss.52-5, 2011 (SCI-Expanded)

52. The prognostic relevance of response evaluation to chemotherapy by FDG-PET/CT in patients with metastatic non-small cell lung cancer

Ordu C., Selcuk N. A., Akosman C., Oyan B.

JOURNAL OF CLINICAL ONCOLOGY , cilt.29, sa.15, 2011 (SCI-Expanded) Sürdürülebilir Kalkınma

53. The prognostic relevance of response evaluation to chemotherapy by FDG-PET/CT in patients with metastatic non-small cell lung cancer

Ordu C., Selcuk N. A., Akosman C., Oyan B.

JOURNAL OF CLINICAL ONCOLOGY , cilt.29, sa.15, 2011 (SCI-Expanded) Sürdürülebilir Kalkınma

54. The acute effects of palonosetron on ECG parameters in patients with cancer

Akosman C., Ordu C., Oyan B.

JOURNAL OF CLINICAL ONCOLOGY , cilt.29, sa.15, 2011 (SCI-Expanded) Sürdürülebilir Kalkınma

55. High complete remission rate and durable remissions achieved with rational use of autologous stem-cell transplantation, thalidomide maintenance, and non-myeloablative allogeneic transplantation in patients with multiple myeloma.

Oyan B., Koc Y., Ozdemir E., Kars A., Turker A., Tekuzman G., et al.

Clinical transplantation , cilt.23, ss.839-47, 2009 (SCI-Expanded)

56. Validation of FDG-PET/CT in evaluation of early remission in patients with refractory lymphoma after treatment with high dose chemotherapy (HDT) and autologous stem cell transplantation (ASCT)

Selcuk N. A., Civi G., Toklu T., Oyan B.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING , cilt.36, 2009 (SCI-Expanded)

57. The acute effect of trastuzumab infusion on ECG parameters in metastatic breast cancer patients.

Yavas O., Yazici M., Eren O., Oyan B.

Swiss medical weekly , cilt.137, ss.556-8, 2007 (SCI-Expanded) Sürdürülebilir Kalkınma

58. Hemorrhagic cystitis due to viral infection following hematopoietic stem cell transplantation

Obek C., Kocagoz T., Aktas S., Yencilek F., Uluc B., Koc Y.

JOURNAL OF ENDOUROLOGY , cilt.21, 2007 (SCI-Expanded)

59. Current medical treatment of pancreatic neuroendocrine tumors

Yalcin S., Oyan B., Bayraktar Y.

HEPATO-GASTROENTEROLOGY , cilt.54, sa.73, ss.278-284, 2007 (SCI-Expanded)

60. High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma.

Oyan B., Koc Y., Ozdemir E., Kars A., Turker A., Tekuzman G., et al.

Leukemia & lymphoma , cilt.47, ss.1545-52, 2006 (SCI-Expanded)

61. Adding a single high-dose chemotherapy cycle to three cycles of standard salvage chemotherapy for relapsed germ-cell tumours does not improve clinical outcomes.

Oyan B.

Cancer treatment reviews , cilt.32, ss.45-9, 2006 (SCI-Expanded)

62. Is it time to discontinue using high-dose chemotherapy for salvage of patients with advanced germ-cell tumors failing first-line platinum chemotherapy?

Oyan B., Koc Y.

Annals of oncology : official journal of the European Society for Medical Oncology , cilt.17, ss.349-50, 2006 (SCI-Expanded)

63. Prevalence and correlates of metabolic syndrome (MS) in older adults.

Cankurtaran M., Halil M., Yavuz B., Dagli N., Oyan B., Ariogul S.

Archives of gerontology and geriatrics , cilt.42, ss.35-45, 2006 (SCI-Expanded)

64. Improvement of chronic pulmonary graft-vs-host disease manifesting as bronchiolitis obliterans organizing pneumonia following extracorporeal photopheresis

Oyan B., Koc Y., Emri S., Kansu E.

MEDICAL ONCOLOGY , cilt.23, sa.1, ss.125-129, 2006 (SCI-Expanded)

65. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-hodgkin lymphoma: A salvage regimen with high response rates before autologous stem cell transplantation

Oyan B., Koc Y., Ozdemir E., Kars A., Turker A., Tekuzman G., et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION , cilt.11, sa.9, ss.688-697, 2005 (SCI-Expanded)

66. IIVP salvage regimen induces high response rates in patients with relapsed lymphoma before autologous stem cell transplantation

Abali H., Oyan B., Koc Y., Kars A., Barista I., ÜNER A., et al.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS , cilt.28, sa.3, ss.264-269, 2005 (SCI-Expanded)

67. Successful salvage with high-dose sequential chemotherapy coupled with in vivo purging and autologous stem cell transplantation in 2 patients with primary refractory mantle cell lymphoma presenting in the leukemic phase

Oyan B., Koc Y., Kansu E.

INTERNATIONAL JOURNAL OF HEMATOLOGY , cilt.81, sa.2, ss.155-158, 2005 (SCI-Expanded)

68. Alprazolam significantly improves the efficacy of granisetron in the prophylaxis of emesis secondary to moderately emetogenic chemotherapy in patients with breast cancer

Abali H., Oyan B., Guler N.

CHEMOTHERAPY , cilt.51, sa.5, ss.280-285, 2005 (SCI-Expanded)

69. A randomized trial of continuous infusion versus bolus mitoxantrone in combination with cytarabine in newly diagnosed patients with acute myeloblastic leukemia

Koc Y., Oyan B., Kars A., Tekuzman G., Canpinar H., Kansu E.

HEMATOLOGICAL ONCOLOGY , cilt.22, sa.2, ss.43-53, 2004 (SCI-Expanded)

70. Does letrozole have any place in adjuvant setting in breast cancer patients with documented hypercoagulability?

Oyan B., Altundag K., Ozisik Y.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS , cilt.27, sa.2, ss.210-211, 2004 (SCI-Expanded)

71. Prognostic factors and outcome in 306 patients with diffuse large B-cell lymphoma (DLBCL)

Oyan B., Tekuzman G., BARIŞTA İ., Ozisik Y., kars A., Turker A., et al.

ANNALS OF ONCOLOGY , cilt.15, ss.153, 2004 (SCI-Expanded)

72. Epithelioid sarcoma of vulva - A case report and review of the literature

Altundag K., Dikbas O., Oyan B., Usubutun A., Turker A.

MEDICAL ONCOLOGY , cilt.21, sa.4, ss.367-372, 2004 (SCI-Expanded)

73. Idiopathic fibrosclerosis of bilateral orbits, bilateral ureters, thyroid: a case report and review of the literature.

Cankurtaran M., Oyan B., Kiliçkap S., Yavuz B., Batman F.

International urology and nephrology , cilt.36, ss.495-8, 2004 (SCI-Expanded)

74. Thymic malignancy in a breast cancer patient - Is there an association with anti-estrogenic effects of tamoxifen?

Oyan B., Aksoy S., Yavas O., Kars A., Turker A., Barista I.

ACTA ONCOLOGICA , cilt.43, sa.1, ss.115-116, 2004 (SCI-Expanded)

75. Breast cancer and splenic non-Hodgkin's lymphoma, a rare occurrence [1]

Engin H., Baltali E., Oyan B., Göksel H., Demirel B.

Breast Journal , cilt.8, sa.6, ss.400-401, 2002 (SCI-Expanded) Sürdürülebilir Kalkınma

76. Generalized lymphadenopathy - A rare presentation of disseminated prostate cancer

Oyan B., Engin H., Yalcin S.

MEDICAL ONCOLOGY , cilt.19, sa.3, ss.177-179, 2002 (SCI-Expanded)

Diğer Dergilerde Yayınlanan Makaleler 10

1. Immunotherapy for Lung Cancer

Karadurmuş N., AKYÜREK N., AYDINER A., SAVAŞ R., SÖNMEZ Ö., ŞENDUR M. A. N., et al.

Journal of Oncological Science , cilt.9, sa.2, ss.97-111, 2023 (Scopus)

2. Three Cases of Breast Metastases from Lung Cancer and Systematic Review of the Literature

Güldoğan N., Esen İçten G., Tokat F., Tutar B., Kara H., Korkmaz T., et al.

EUROPEAN JOURNAL OF BREAST HEALTH , cilt.17, sa.2, ss.200-205, 2021 (ESCI) Sürdürülebilir Kalkınma

3. Side effects and management: Osteonecrosis of jaw and acute phase reaction

Oyan B.

Turk Onkoloji Dergisi , cilt.36, ss.79-80, 2021 (ESCI)

4. Bone-targeted agents used in breast cancer patients with bone metastases

Oyan B.

Turk Onkoloji Dergisi , cilt.36, ss.54-55, 2021 (ESCI)

5. Turkish national consensus on breast cancer management during temporary state of emergency due to COVID-19 outbreak

Sezer A., ÇİÇİN İ., Cakmak G. K., Gurdal S. O., Basaran G., Oyan B., et al.

TURKISH JOURNAL OF SURGERY , cilt.36, sa.2, ss.147-163, 2020 (ESCI)

6. An unusual cause of arthritis: Carcinoma metastases

ÖZLER T., SÖNMEZ Ö., EREN O. Ö., DOĞAN EKİCİ A. I., GÜVEN M., ÇAĞATAY U., et al.

Yeditepe Medical Journal , 2014 (Hakemli Dergi)

7. Successful allogeneic marrow transplantation from donors with hematologic malignancies

Koç Y., Oyan B., Akhtar M. S., Schenkein D. P., Miller K. B.

Turkish Journal of Cancer , cilt.34, sa.3, ss.118-121, 2004 (Scopus)

8. Hematopoietic stem cell transplantation in hematologic malignancies and solid tumors: Hacettepe University Institute of Oncology experience

Oyan B., Koç Y., Kars A., Türker A., Akyüz C., Güç D., et al.

Turkish Journal of Cancer , cilt.33, sa.1, ss.27-39, 2003 (Scopus)

9. The prognostic factors for local disease free survival and distant disease free survival in stage I-III breast cancer patients treated with adjuvant cyclophosphamide-adriamycin-5-fluorouracil (CAF) chemotherapy Adjuvan siklofosfamid-adriamisin-5-florourasil (CAF) kemoterapisi alan opere evre I-III meme kanserli hastalarda lokal nükssüz ve uzak nükssüz saǧkalimi etkileyen prognostik faktörler

Oyan B., Güler N., Tekuzman G., Kars A., Türker A., Altundaǧ M. K., et al.

THOD - Turk Hematoloji-Onkoloji Dergisi , cilt.12, sa.3, ss.115-125, 2002 (Scopus) Sürdürülebilir Kalkınma

10. The prognostic predictors for disease free survival and overall survival in stage I-III breast cancer patients treated with adjuvant cyclophosphamideadriamycin-5-fluorouracil (CAF) chemotherapy

Oyan B., Güler N., Kars A., Türker A., Altundaǧ K., Özişik Y., et al.

Turkish Journal of Cancer , cilt.32, sa.3, ss.92-104, 2002 (Scopus) Sürdürülebilir Kalkınma

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 39

1. Artificial intelligence algorithms for recurrence risk score prediction in early-stage breast cancer: A multicenter study of 437 cases

Bayram E., Basaran G., Gokmen E., Mandel N. M., Oyan B., Uskent N., et al.

Special Clinical Science Symposia, ELECTR NETWORK, 29 Mayıs 2024, (Özet Bildiri)

2. The Health Impact Projection Model of the PD-1/PD-L1 Inhibitor Class in Cancer Care in Turkey

Akpamuk U., Hughes R., Swales O., Oyan Uluç B., Kılıçkap S., Demirci U., et al.

ISPOR 2022, Washington, Amerika Birleşik Devletleri, 15 - 18 Mayıs 2022, ss.193, (Özet Bildiri)

3. Efficacy of regarafenib and 5-Fluorasil-based rechallenge treatment in the third-line treatment of metastaic colorectal cancer : A Turkısh oncology group study

Şenocak Taşçı E., Oyan B., Sönmez Ö.

ASCO GI, California, Amerika Birleşik Devletleri, 20 - 22 Ocak 2022, ss.1, (Özet Bildiri)

4. Talazoparib in locally advanced or metastatic breast cancer patients: Experience from an early access program in Turkey

ŞENDUR M. A. N., Cakar B., Hizal M., Eraslan E., AKSOY S., PAYDAŞ S., et al.

ESMO Breast Cancer Virtual Congress, ELECTR NETWORK, 5 - 08 Mayıs 2021, cilt.32, (Özet Bildiri)

5. Relationship of Vitamin D Receptor Gene Polymorphisms with Adverse Drug Responses In Patients With Colorectal Cancer

Tosun M., ÇEVİK M., SÖNMEZ Ö., ER Ö., DEMİR O. G., OYAN ULUÇ B., et al.

9th International Molecular Biology and Biotechnology Congress, 6 - 10 Aralık 2020, (Özet Bildiri) Sürdürülebilir Kalkınma

6. Retrospective analysis of ribociclib and letrozole as first-line therapy in patients with hormone receptor (HR) positive metastatic breast cancer (MBC) within a managed access program (MAP) in Turkey

Başaran G., Demirci U., Yıldız F., Çiçin İ., Aktaş B. Y., Öztürk B., et al.

American Society of Clinical Oncology (ASCO) Annual Meeting, Illinois, Amerika Birleşik Devletleri, 29 - 31 Mayıs 2020, ss.13055, (Özet Bildiri) Sürdürülebilir Kalkınma

7. Retrospective analysis of ribociclib and letrozole as first-line therapy in patients with hormone receptor (HR) positive metastatic breast cancer (MBC) within a managed access program (MAP) in Turkey.

Basaran G., Demirci U., Yildiz F., Cicin I., Aktas B. Y., Ozturk B., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 - 31 Mayıs 2020, cilt.38, (Özet Bildiri)

8. Risks and characteristics of early-onset colorectal cancer: A single center retrospective study

Yazar A., Koç E. S., Tözün A. N., Kutsal N. E., Önder F. O., Aygün C., et al.

Proceedings of the World Congress of Gastroenterology, İstanbul, Türkiye, 21 - 24 Eylül 2019, ss.383, (Özet Bildiri) Sürdürülebilir Kalkınma

9. OnkoTürk Kayıt Sistemi: Solid Organ Maligniteli Hastalarda Tedavi ve İzlem Tercihlerinin Belirlenmesine Yönelik Kayıt Çalışması Ara Değerlendirme Sonuçları

Alan Ö., Yumuk P. F., Dane F., Akgül Babacan N., Coşkun H. Ş., Sezgin Göksu S., et al.

23. Ulusal Kanser Kongresi, Antalya, Türkiye, 17 - 21 Nisan 2019, ss.292, (Özet Bildiri)

10. Distribution of ADC-Ki67 with molecular subtypes labels

Aksoy Özcan Ü., Ulus S., Ekemen S., Oyan Uluç B., Ozcan İ. A.

25th European Congress of Radiology (ECR) 2019, Vienna, Avusturya, 27 Şubat - 03 Mart 2019, ss.1, (Özet Bildiri)

11. Distribution of ADC-Ki67 with molecular subtypes labels

ÖZCAN K. Ü., ULUS BUTURAK Ö. S., EKEMEN S., OYAN ULUÇ B., ÖZCAN İ. A.

European Society of Radiology, Viyana, Avusturya, 27 Şubat - 03 Mart 2019, (Tam Metin Bildiri)

12. Correlation of proliferation index markers (Ki-67 and PHH3) with breast MRI apparent diffusion coefficient values

EKEMEN S., ÖZCAN İ. A., ÖZCAN K. Ü., ULUS BUTURAK Ö. S., OYAN ULUÇ B.

SAN ANTONIO BREAST CANSER SYMPOSIUM, San-Antonio, Kuzey Mariana Adaları, 4 - 08 Aralık 2018, cilt.79, ss.5, (Tam Metin Bildiri)

13. Correlation of proliferation index markers (Ki-76 and PHH3) with breast MRI apparent diffusion coefficient values

Ekemen S., Özcan A., Aksoy Özcan Ü., Ulus S., Oyan Uluç B.

San Antonio Breast Cancer Symposium, Texas, Amerika Birleşik Devletleri, 4 - 10 Aralık 2018, cilt.79, sa.4, ss.5, (Özet Bildiri) Sürdürülebilir Kalkınma

14. Testing machine learning algorithms' performance for non-invasively identifying breast cancer molecular subtypes using BI-RADS evaluations

Özcan İ. A., Aksoy Özcan Ü., Ekemen S., Ulus S., Oyan Uluç B.

San Antonio Breast Cancer Symposium, Texas, Amerika Birleşik Devletleri, 4 - 10 Aralık 2018, cilt.79, sa.4, ss.5, (Özet Bildiri) Sürdürülebilir Kalkınma

15. Pertuzumab, trastuzumab and taxane combination for visceral organ metastatic patients: Real life practice results

Esin E., Oksuzoglu O. B. C., Bilici A., ÇİÇİN İ., AKSOY S., Alacacioglu A., et al.

43rd ESMO Congress (ESMO), Munich, Almanya, 19 - 23 Ekim 2018, cilt.29, ss.104-105, (Özet Bildiri)

16. Comparison of SP142 (Ventana) and SP263 (Ventana) assays to test PD-L1 expression in metastatic cancer patients to be treated with immune checkpoint inhibitors

Oyan Uluç B., Sönmez Ö., Yazar A., Teomete M.

American Society of Clinical Oncology (ASCO) Annual Meeting, Illinois, Amerika Birleşik Devletleri, 1 - 05 Haziran 2018, ss.2436, (Özet Bildiri) Sürdürülebilir Kalkınma

17. TÜRKIYE’DE METASTATIK MEME KANSERINDE HER2 HEDEFLITEDAVIDE PERTUZUMAB KULLANIMI ERKEN DÖNEM GÜVENLILIKVERILERI

ESİN E., ÇAKMAK ÖKSÜZOĞLU Ö. B., SAKİN A., YILDIRIM N., ÇABUK D., KARAAĞAÇ M., et al.

7. TÜRK TIBBİ ONKOLOJİ KONGRESİ, Türkiye, 21 - 24 Mart 2018, (Özet Bildiri)

18. Change of PD-L1 expression status of high grade glial tumors at recurrence and its effect on survival

Oyan B., Eren S., Sonmez O., Ozkan F., Yaltirak K., Ture U.

42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid, İspanya, 8 - 12 Eylül 2017, cilt.28, (Özet Bildiri)

19. PD-L1 expression of high grade glial tumors at diagnosis and change of expression status at recurrence.

Oyan B., Eren S., Sonmez Ö., Ozkan F., Yaltirak K., Ture U.

53rd Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 2 - 06 Haziran 2017, cilt.35, (Özet Bildiri)

20. Immunotherapy releated cardiomyopathy.

Sonmez Ö., Sever O. N., Oyan B., Demir O. G.

53rd Annual Clinical Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 2 - 07 Haziran 2017, cilt.35, (Özet Bildiri)

21. Primary peritoneal hepatoid adenocarcinoma: Response to platin based chemotherapy.

Oyan B., Sonmez Ö., Eren O. O., Ozkan F., Ozgen A.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 3 - 07 Haziran 2016, cilt.34, (Özet Bildiri)

22. The change in the status of MGMT methylation and IDH mutation in initial and recurrent glial tumors and its relation with prognosis.

Oyan B., Ozturk M. A., Ozkan F., Eren O. O., Sonmez Ö.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri)

23. Capecitabine maintenance after first-line induction chemotherapy with docetaxel cisplatin, and fluorouracil in patients with advanced gastric cancer

Oyan B., Eren O. O., Sonmez Ö.

50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, Amerika Birleşik Devletleri, 30 Mayıs - 03 Haziran 2014, cilt.32, (Özet Bildiri) Sürdürülebilir Kalkınma

24. Gallbladder perforation related to bevacizumab in a patient with lung adenocarcinoma.

Oyan B., Ozturk M. A., Kalayci M.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri)

25. The comparison of up-front autologous peripheral stem cell transplantation in first remission and long-lasting intensive chemotherapy protocols in highly aggressive non-Hodgkin's lymphomas: Results of a retrospective analysis.

Ozturk M., Ozaydin S., Oyan B., ÖZBALAK M. M., Arpaci F., Paydas S., et al.

48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 1 - 06 Haziran 2012, cilt.30, (Özet Bildiri)

26. Hematopoietic stem cell transplantation for hematological diseases at yeditepe university hospital

Yirmibescik S., Senkal V., Kalayci G., Aktas S., Aydin D., Sonmezoglu M., et al.

Tandem BMT Meeting 2007, Colorado, Amerika Birleşik Devletleri, 8 - 12 Şubat 2007, cilt.13, ss.94, (Özet Bildiri)

27. Nephrologic complications in stem cell transplantation

Yakupoglu Ü., Uluc B., Koc Y.

44th ERA-EDTA Congress, Barcelona, İspanya, 22 - 24 Haziran 2007, cilt.22, ss.56-57, (Özet Bildiri)

28. Tropisetron does not induce arrhythmia in chemo-naive otherwise healthy cancer patients.

Abali H., Abali G., Oksuzoglu B., Bakar M., Budakoglu B., Oyan B., et al.

41st Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, Amerika Birleşik Devletleri, 13 - 17 Mayıs 2005, cilt.23, (Özet Bildiri)

29. High-dose sequential chemotherapy coupled with autologous PBSCT and in vivo purging with rituximab in patients with relapsed/refractory or high-risk B-cell NHL

Oyan B., Koc Y., Ozdemir E., Kansu E.

31st Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/21st Meeting of the EBMT-Nurses-Group/4th Meeting of the EBMT-Data-Management-Group, Prague, Çek Cumhuriyeti, 20 - 23 Mart 2005, cilt.35, (Özet Bildiri)

30. Nonmyeloablative allogeneic stem cell transplantation: Hacettepe University Institute of Oncology Experience.

Koc Y., Ozdemir E., Oyan B., Kansu E.

46th Annual Meeting of the American-Society-of-Hematology, California, Amerika Birleşik Devletleri, 4 - 07 Aralık 2004, cilt.104, (Özet Bildiri)

31. High-dose sequential chemotherapy (HDSC) in support of autologous stem cell transplantation (ASCT) in patients with relapsed/refractory Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL)

Oyan B., Koc Y., Ozdemir E., Kansu E.

46th Annual Meeting of the American-Society-of-Hematology, California, Amerika Birleşik Devletleri, 4 - 07 Aralık 2004, cilt.104, (Özet Bildiri)

32. Granisetron plus alprazolam versus granisetron alone in the control of emesis in patients with operable breast cancer receiving anthracycline containing chemotherapy: A phase III trial.

Abali H., Oyan B., Ozisik Y., Guler N.

40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, Amerika Birleşik Devletleri, 5 - 08 Haziran 2004, cilt.22, (Özet Bildiri) Sürdürülebilir Kalkınma

33. Clinicopathological features and outcome of primary gastric lymphoma: A series of 73 cases

Oyan B., Tekuzman G., Barista I., Kars A., Turker A., Ozisik Y., et al.

40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, Amerika Birleşik Devletleri, 5 - 08 Haziran 2004, cilt.22, (Özet Bildiri)

34. Outcome of well differentiated thyroid cancer: Single institution results.

Aksoy S., Abali H., Kilickap S., Yavas O., Oyan B., ELKIRAN E. T., et al.

40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, Amerika Birleşik Devletleri, 5 - 08 Haziran 2004, cilt.22, (Özet Bildiri)